|
|
 | | | |
- close
- close
- close
- close
QUOTE AND NEWS
Globe Newswire
Apr 10
Comment
TORONTO, April 10, 2012 (GLOBE NEWSWIRE) -- GeneNews Limited (TSX:GEN), a company focused on developing and commercializing blood-based biomarker tests for the early detection of diseases and personalized health management, announced that Enzo
Business Wire
Apr 10
Comment
Enzo Biochem Inc. (NYSE: ENZ) today announced the launch of the ColonSentry™ test for assessing a patient’s risk of having colorectal cancer, the first in a pipeline of new molecular diagnostic products the Company plans for the medical
Business Wire
Apr 1
Comment
Enzo Biochem Inc. (NYSE:ENZ) announced that the Company yesterday made its first peer-reviewed presentation of its novel AmpiProbe™ platform, encompassing low cost, and high sensitivity, real time nucleic acid amplification and detection assays, at
Business Wire
Mar 20
Comment
Enzo Biochem Inc. (NYSE: ENZ) announced today an expanded business arrangement between its wholly owned subsidiary, Enzo Life Sciences, and Tokyo-based Cosmo Bio Co., Ltd. (JASDAQ: 3386). Under the terms of the arrangement, Cosmo Bio—a distributor
Business Wire
Mar 13
Comment
Enzo Biochem Inc. (NYSE:ENZ) announced today the filing of an application with the New York State Department of Health for the first assay based on its proprietary AmpiProbe™ nucleic acid detection platform. Upon approval, the Company plans to
Business Wire
Mar 12
Comment
Enzo Biochem Inc. (NYSE:ENZ) today reported improved results for the fiscal quarter ended January 31, 2012. Among the quarter’s highlights: Total revenues increased 5% year over year, led by strong organic growth at Enzo Clinical Labs and increased
Business Wire
Mar 8
Comment
Enzo Biochem, Inc. (NYSE:ENZ), will hold a conference call to discuss fiscal 2012 second quarter results on Tuesday, March 13, 2012, at 8:30 AM E.T. To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024.
Benzinga
Feb 21
Comment
Enzo Biochem, Inc. (NYSE: ENZ) today announced that the New York State Department of Health has approved Enzo Clinical Labs' use of the ColonSentry™ test for providing an assessment of a patient's risk of having colorectal cancer. The...
Expert's Economic Outlook, Global - Equity Research on Impax Laboratories Inc and Enzo Biochem, Inc.
Marketwire
Oct 7
Comment
MACAU -- (Marketwire) -- 10/07/11 -- Today, www.EquityMarketsInc.com announced its research report highlighting Impax Laboratories Inc (NASDAQ: IPXL) and Enzo Biochem, Inc. (NYSE: ENZ). Full content and research is available at
StreetInsider.com
Jul 6
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Enzo+Biochem+%28ENZ%29+Unit+Updates+on+Sulfated+Tyrosine/6621334.html for the full story.
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
